HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.

Authors:

Shore N, George D, Saad F, et al.

Year

2020

Conference

ASCO Annual Meeting

Location

Virtual

Start Date

May 29

End Date

Jun 2